Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study

Aiichiro Nakajima,1 Ayako Kanie,1 Masaya Ito,1 Naotsugu Hirabayashi,2 Fumi Imamura,3 Yoshitake Takebayashi,1,4 Masaru Horikoshi1 1National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Tokyo, Japan; 2Department of Psychiatry, National Center of Neur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nakajima A, Kanie A, Ito M, Hirabayashi N, Imamura F, Takebayashi Y, Horikoshi M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	psychiatric diseases depression acquired dependency discontinuation Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a8b4d254e18b4bc387c6f7a11c1ee1f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a8b4d254e18b4bc387c6f7a11c1ee1f1
record_format	dspace
spelling	oai:doaj.org-article:a8b4d254e18b4bc387c6f7a11c1ee1f12021-12-02T13:07:11ZCognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study1178-2021https://doaj.org/article/a8b4d254e18b4bc387c6f7a11c1ee1f12020-09-01T00:00:00Zhttps://www.dovepress.com/cognitive-behavioral-therapy-reduces-benzodiazepine-anxiolytics-use-in-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Aiichiro Nakajima,1 Ayako Kanie,1 Masaya Ito,1 Naotsugu Hirabayashi,2 Fumi Imamura,3 Yoshitake Takebayashi,1,4 Masaru Horikoshi1 1National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Tokyo, Japan; 2Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; 3Department of Clinical Psychology, National Center of Neurology and Psychiatry, Tokyo, Japan; 4Department of Health Risk Communication, School of Medicine, Fukushima Medical University, Fukushima, JapanCorrespondence: Aiichiro NakajimaNational Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8551, JapanTel +81-42-341-2711Fax +81-42-346-1944Email aiichiro.nakajima@ncnp.go.jpPurpose: Benzodiazepines (BZDs) are prescribed to treat psychiatric diseases. However, many guidelines recommend limiting the use of BZDs because of side effects and lack of evidence regarding long-term efficacy. Moreover, reducing BZDs’ use is difficult because of dependency and the severity of withdrawal symptoms. The efficacy of cognitive behavioral therapy (CBT) for mood and anxiety disorders has been demonstrated. However, there is scant evidence that CBT has effectively reduced BZDs use, especially in Japan, where the BZDs prescription rate is high. Therefore, we sought to examine the impact of CBT on reducing BZDs use in a Japanese psychiatric setting.Patients and Methods: Participants were outpatients with mood and anxiety disorders who were prescribed BZD anxiolytics. We retrospectively reviewed changes in BZD anxiolytics prescription dosages during CBT (66 patients; mean number of CBT sessions, 14.6) from our hospital record between April 2015 and September 2017. We checked prescriptions at four time points: at first interview for judging adaptation of CBT (baseline), at the first CBT session, at the last CBT session, and 3 months after the last CBT session.Results: A total of 13 of 66 patients discontinued BZD anxiolytics during CBT, and 21 of 66 reduced their prescribed dosage by 50%. The association between discontinuation and dose-reduction and assessment period was modeled simultaneously using Bayesian hierarchical hurdle model. Results from the modeling showed a significant discontinuation at post-CBT and at 3 months post-CBT session compared to baseline (estimated median odds ratio [OR] post-CBT = 9.79 [95% CI: 4.65– 20.45]; OR at 3 months post-CBT = 11.53 [95% CI: 6.06– 22.33]). Moreover, a significant dose reduction was observed post-intervention (estimated median relative risk = 0.845 [95% CI: 0.729– 0.982]), with a median reduction of 1.7 mg (diazepam conversion) in BZD use.Conclusion: Our results suggest that CBT possibly aids in reducing and discontinuing BZD anxiolytics use for Japanese patients.Keywords: psychiatric diseases, depression, acquired dependency, discontinuationNakajima AKanie AIto MHirabayashi NImamura FTakebayashi YHorikoshi MDove Medical Pressarticlepsychiatric diseasesdepressionacquired dependencydiscontinuationNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 2135-2142 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	psychiatric diseases depression acquired dependency discontinuation Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	psychiatric diseases depression acquired dependency discontinuation Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Nakajima A Kanie A Ito M Hirabayashi N Imamura F Takebayashi Y Horikoshi M Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
description	Aiichiro Nakajima,1 Ayako Kanie,1 Masaya Ito,1 Naotsugu Hirabayashi,2 Fumi Imamura,3 Yoshitake Takebayashi,1,4 Masaru Horikoshi1 1National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Tokyo, Japan; 2Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo, Japan; 3Department of Clinical Psychology, National Center of Neurology and Psychiatry, Tokyo, Japan; 4Department of Health Risk Communication, School of Medicine, Fukushima Medical University, Fukushima, JapanCorrespondence: Aiichiro NakajimaNational Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, 4-1-1, Ogawahigashi, Kodaira, Tokyo 187-8551, JapanTel +81-42-341-2711Fax +81-42-346-1944Email aiichiro.nakajima@ncnp.go.jpPurpose: Benzodiazepines (BZDs) are prescribed to treat psychiatric diseases. However, many guidelines recommend limiting the use of BZDs because of side effects and lack of evidence regarding long-term efficacy. Moreover, reducing BZDs’ use is difficult because of dependency and the severity of withdrawal symptoms. The efficacy of cognitive behavioral therapy (CBT) for mood and anxiety disorders has been demonstrated. However, there is scant evidence that CBT has effectively reduced BZDs use, especially in Japan, where the BZDs prescription rate is high. Therefore, we sought to examine the impact of CBT on reducing BZDs use in a Japanese psychiatric setting.Patients and Methods: Participants were outpatients with mood and anxiety disorders who were prescribed BZD anxiolytics. We retrospectively reviewed changes in BZD anxiolytics prescription dosages during CBT (66 patients; mean number of CBT sessions, 14.6) from our hospital record between April 2015 and September 2017. We checked prescriptions at four time points: at first interview for judging adaptation of CBT (baseline), at the first CBT session, at the last CBT session, and 3 months after the last CBT session.Results: A total of 13 of 66 patients discontinued BZD anxiolytics during CBT, and 21 of 66 reduced their prescribed dosage by 50%. The association between discontinuation and dose-reduction and assessment period was modeled simultaneously using Bayesian hierarchical hurdle model. Results from the modeling showed a significant discontinuation at post-CBT and at 3 months post-CBT session compared to baseline (estimated median odds ratio [OR] post-CBT = 9.79 [95% CI: 4.65– 20.45]; OR at 3 months post-CBT = 11.53 [95% CI: 6.06– 22.33]). Moreover, a significant dose reduction was observed post-intervention (estimated median relative risk = 0.845 [95% CI: 0.729– 0.982]), with a median reduction of 1.7 mg (diazepam conversion) in BZD use.Conclusion: Our results suggest that CBT possibly aids in reducing and discontinuing BZD anxiolytics use for Japanese patients.Keywords: psychiatric diseases, depression, acquired dependency, discontinuation
format	article
author	Nakajima A Kanie A Ito M Hirabayashi N Imamura F Takebayashi Y Horikoshi M
author_facet	Nakajima A Kanie A Ito M Hirabayashi N Imamura F Takebayashi Y Horikoshi M
author_sort	Nakajima A
title	Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
title_short	Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
title_full	Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
title_fullStr	Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
title_full_unstemmed	Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study
title_sort	cognitive behavioral therapy reduces benzodiazepine anxiolytics use in japanese patients with mood and anxiety disorders: a retrospective observational study
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/a8b4d254e18b4bc387c6f7a11c1ee1f1
work_keys_str_mv	AT nakajimaa cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy AT kaniea cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy AT itom cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy AT hirabayashin cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy AT imamuraf cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy AT takebayashiy cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy AT horikoshim cognitivebehavioraltherapyreducesbenzodiazepineanxiolyticsuseinjapanesepatientswithmoodandanxietydisordersaretrospectiveobservationalstudy
_version_	1718393463121117184

Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study

Ejemplares similares